Oryon Cell Therapies Unveils Autologous Neuron Replacement Therapy for Parkinson’s Disease
Oryon Cell Therapies, a clinical-stage biotech company, has emerged from stealth mode to focus on developing an autologous neuron replacement therapy for Parkinson’s disease and other neurodegenerative disorders. The company has secured $42 million in funding, including a new $21 million Series A tranche, to support the completion of its Phase 1b/2a clinical trial. Ron … Read more